💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rabeprazole

CHEMBL1219 Phase 4 Approved Small molecule
Half-Life
1-2 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
359.4 g/mol
LogP
1.9
Phase
4

A proton pump inhibitor that reduces stomach acid production, used to treat gastroesophageal reflux disease, stomach ulcers, and related conditions. It provides relief from heartburn and helps the esophagus heal from acid damage.

Molecular Weight

359.4440 g/mol

LogP

1.90

TPSA

96.30 Ų

Lipinski RO5

Pass

Therapeutic Areas

Asthma Atrial Fibrillation Bladder Cancer Breast Cancer Colorectal Cancer Gastroesophageal Reflux Disease Infectious Disease Insomnia Lymphoma Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Thyroid Cancer

Drug Classes

A — A - Alimentary Tract and Metabolism

Mechanism of Action

Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

Pharmacokinetics (PK)

Half-Life 1-2 hours

Pharmacodynamics (PD)

Mechanism

Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C

                

                

                
                

                    
InChI

                    
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H21N3O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Rotatable Bonds

                        
8

                    

                    
                    
                    

                        
Heavy Atoms

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
A proton pump inhibitor that reduces stomach acid production, used to treat gastroesophageal reflux disease, stomach ulcers, and related conditions. It provides relief from heartburn and helps the esophagus heal from acid damage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Proton pump inhibitor irreversibly inhibiting gastric H+/K+-ATPase with faster onset than omeprazole.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Rabeprazole: Half-life: 1-2 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Rabeprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Canagliflozin
                            Small molecule
                        
                        
                        
                            Dapagliflozin
                            Small molecule
                        
                        
                        
                            Dulaglutide
                            Protein
                        
                        
                        
                            Empagliflozin
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1219.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5029.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.